Sarepta Therapeutics (SRPT.O) said on Monday it will resume shipping of its muscular disorder gene therapy to patients who can walk, sending the company's shares 59% higher in extended trading.

The Food and Drug Administration has given Sarepta Therapeutics a green light to resume shipping its gene therapy Elevidys to some patients with Duchenne muscular dystrophy, a little over one week af...

While Sarepta’s challenges could push some away from investing in gene therapies, it could also lead to interest in different approaches.